Page last updated: 2024-11-04

temozolomide and Opportunistic Infections

temozolomide has been researched along with Opportunistic Infections in 11 studies

Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.

Research Excerpts

ExcerptRelevanceReference
"Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases."7.88Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018)
"Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia."7.74Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007)
"Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine."7.72Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004)
"Treatment of malignant gliomas has changed substantially over the last few years."5.35Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009)
"Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma."4.86Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010)
"Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases."3.88Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018)
"Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia."3.74Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007)
"Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine."3.72Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004)
"Treatment of malignant gliomas has changed substantially over the last few years."1.35Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009)
"We report the case of a patient with primary brain tumor who developed cytomegalovirus associated colonic pseudotumor as an opportunistic infection while receiving chemotherapy with Temozolomide and radiation."1.35Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. ( De Jesus, A; Grossman, SA; Paun, O, 2009)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jbeli, AH1
Yu, J1
Furukawa, R1
Homma, H1
Inoue, T1
Horiuchi, H1
Usui, K1
Gorospe Sarasúa, L1
Ureña-Vacas, A1
Muñoz Del Toro, JR1
Yaman, E1
Coskun, U1
Ozturk, B1
Buyukberber, S1
Kaya, AO1
Coskun, O1
Buyukberber, N1
Yildiz, R1
Benekli, M1
De Jesus, A1
Grossman, SA1
Paun, O1
Gousias, K1
Konstantinos, G1
Kyritsis, A1
Athanasios, K1
Meije, Y1
Lizasoain, M1
García-Reyne, A1
Martínez, P1
Rodríguez, V1
López-Medrano, F1
Juan, RS1
Lalueza, A1
Aguado, JM1
Gajewski, TF1
Su, YB1
Sohn, S1
Krown, SE1
Livingston, PO1
Wolchok, JD1
Quinn, C1
Williams, L1
Foster, T1
Sepkowitz, KA1
Chapman, PB1
Schwarzberg, AB1
Stover, EH1
Sengupta, T1
Michelini, A1
Vincitore, M1
Baden, LR1
Kulke, MH1
Choi, JD1
Powers, CJ1
Vredenburgh, JJ1
Friedman, AH1
Sampson, JH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621]Phase 2135 participants (Actual)Interventional2019-03-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for temozolomide and Opportunistic Infections

ArticleYear
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jun-15, Volume: 50, Issue:12

    Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infection

2010

Other Studies

10 other studies available for temozolomide and Opportunistic Infections

ArticleYear
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2016, Volume: 69, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi

2016
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
    Internal medicine (Tokyo, Japan), 2018, Oct-15, Volume: 57, Issue:20

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio

2018
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
    Archivos de bronconeumologia, 2016, Volume: 52, Issue:10

    Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera

2016
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2009, Volume: 16, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN

2009
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
    Journal of neuro-oncology, 2009, Volume: 94, Issue:3

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F

2009
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun

2010
Temozolomide for melanoma: new toxicities and new opportunities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M

2004
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar

2004
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
    Cancer investigation, 2007, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her

2007
Cryptococcal meningitis in patients with glioma: a report of two cases.
    Journal of neuro-oncology, 2008, Volume: 89, Issue:1

    Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk

2008